Gregory P Swanson1, Mark Riggs, Michael Hermans. 1. University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA. gswanson@ctrc.net <gswanson@ctrc.net>
Abstract
BACKGROUND: Failure after radical prostatectomy can occur even out to 25 years after surgery. Therefore, it is important that studies have sufficient follow-up to determine more accurately the risk of failure. We evaluated a large cohort of patients for pathologic findings and risk of failure with a median follow-up of 9.5 years. MATERIAL AND METHODS: Between 1985 and 1995, 719 patients underwent radical prostatectomy for lymph node negative prostate cancer. The prostate was inked and evaluated for: (1) positive bladder neck or urethral margin, (2) positive seminal vesicle, (3) into capsule, (4) through capsule, and (5) positive margin. These were considered positive pathologic findings. RESULTS: Overall, 264 (37%) of the patients had biochemical recurrence. For those patients with failure, median time to biochemical recurrence was 2.4 years. Five and 10-year biochemical failure rates were 28% and 38%, respectively. Pathologic stage of disease significantly (<0.0001) predicted for subsequent failure. If there were no positive pathology findings, the recurrence rate was 25%, compared to 63% for any of the 3 findings. Overall, 212 (29%) of the patients have died. Five and 10-year survival were 91% and 75%, respectively. A total of 45 patients (6%) died of prostate cancer. For patients with negative pathology findings, 3% died as a direct consequence of prostate cancer, compared to 13% if the pathology was positive. Of the patients with positive seminal vesicle, 28% died of cancer. CONCLUSION: Patients with any of the following factors have a risk of failure exceeding 40% and are candidates for studies of adjuvant therapy: seminal vesicle involvement, extension through the capsule, or margin involvement.
BACKGROUND: Failure after radical prostatectomy can occur even out to 25 years after surgery. Therefore, it is important that studies have sufficient follow-up to determine more accurately the risk of failure. We evaluated a large cohort of patients for pathologic findings and risk of failure with a median follow-up of 9.5 years. MATERIAL AND METHODS: Between 1985 and 1995, 719 patients underwent radical prostatectomy for lymph node negative prostate cancer. The prostate was inked and evaluated for: (1) positive bladder neck or urethral margin, (2) positive seminal vesicle, (3) into capsule, (4) through capsule, and (5) positive margin. These were considered positive pathologic findings. RESULTS: Overall, 264 (37%) of the patients had biochemical recurrence. For those patients with failure, median time to biochemical recurrence was 2.4 years. Five and 10-year biochemical failure rates were 28% and 38%, respectively. Pathologic stage of disease significantly (<0.0001) predicted for subsequent failure. If there were no positive pathology findings, the recurrence rate was 25%, compared to 63% for any of the 3 findings. Overall, 212 (29%) of the patients have died. Five and 10-year survival were 91% and 75%, respectively. A total of 45 patients (6%) died of prostate cancer. For patients with negative pathology findings, 3% died as a direct consequence of prostate cancer, compared to 13% if the pathology was positive. Of the patients with positive seminal vesicle, 28% died of cancer. CONCLUSION:Patients with any of the following factors have a risk of failure exceeding 40% and are candidates for studies of adjuvant therapy: seminal vesicle involvement, extension through the capsule, or margin involvement.
Authors: Ji Eun Heo; Jee Soo Park; Jong Soo Lee; Jongchan Kim; Won Sik Jang; Nam Hoon Cho; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Won Sik Ham Journal: J Cancer Res Clin Oncol Date: 2019-10-14 Impact factor: 4.553
Authors: Anna E Teeter; Lionel L Bañez; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: J Urol Date: 2008-09-17 Impact factor: 7.450
Authors: Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: Nitin Ohri; Xinglei Shen; Robert B Den; Adam P Dicker; Edouard J Trabulsi; Timothy N Showalter Journal: Cancer Biol Ther Date: 2012-09-06 Impact factor: 4.742
Authors: T Maubon; N Branger; C Bastide; G Lonjon; K-A Harvey-Bryan; P Validire; S Giusiano; D Rossi; X Cathelineau; F Rozet Journal: Prostate Cancer Prostatic Dis Date: 2016-07-12 Impact factor: 5.554
Authors: Mark V Mishra; Eli D Scher; Jocelyn Andrel; Andrew C Margules; Sarah E Hegarty; Edouard J Trabulsi; Terry Hyslop; Robert B Den; Costas D Lallas; Leonard G Gomella; Adam P Dicker; Timothy N Showalter Journal: Am J Clin Oncol Date: 2015-02 Impact factor: 2.339
Authors: T N Showalter; K A Foley; E Jutkowitz; C D Lallas; E J Trabulsi; L G Gomella; A P Dicker; L T Pizzi Journal: Ann Oncol Date: 2011-06-09 Impact factor: 32.976